Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014
SHANGHAI, China, June 28, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) has accepted its Investigational New Drug (IND) application for JS014. In June 2019, Junshi Biosciences and Anwita […]
Read More